Visual Acuity Improvement when Switching from Ranibizumab to Aflibercept is Not Sustained

PURPOSE: To assess whether visual benefits exist in switching to aflibercept in patients who have been chronically treated with ranibizumab for neovascular age-related macular degeneration (nvAMD). METHODS: We performed a multicenter, national electronic medical record database study. Patients under...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Retina
Glavni autori: Lee, Cecilia S., Kim, Alisa J., Baughman, Douglas, Egan, Catherine, Bailey, Clare, Johnston, Robert L., Natha, Salim, Khan, Rehna, Brand, Christopher, Akerele, Toks, McKibbin, Martin, Downey, Louise, Al-Husainy, Saher, Lee, Aaron Y., Tufail, Adnan
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5636644/
https://ncbi.nlm.nih.gov/pubmed/28406859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IAE.0000000000001637
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items